Research Publications:@0.674285:0.063855:0.896201:0.063855:0.896201:0.040840:0.674285:0.040840:0.016980:0.010442:0.009149:0.010442:0.011759:0.010014:0.010442:0.013076:0.005456:0.014370:0.013076:0.013076:0.006538:0.006538:0.010442:0.011759:0.007832:0.006538:0.011759:0.013076:0.009149
Repurposing Synthetic Congeners Of A Natural Product Aurone :@0.104762:0.111208:0.895452:0.111208:0.895452:0.083261:0.104762:0.083261:0.020619:0.012680:0.015878:0.015878:0.012680:0.015878:0.014279:0.011109:0.007939:0.015878:0.014279:0.007140:0.015878:0.014279:0.015878:0.009510:0.015878:0.012680:0.009510:0.007939:0.012680:0.007140:0.020619:0.014279:0.015878:0.014279:0.012680:0.015878:0.012680:0.012680:0.011109:0.007140:0.022218:0.009510:0.005577:0.019048:0.007140:0.020619:0.014279:0.009510:0.015878:0.012680:0.014279:0.007939:0.007140:0.017449:0.012154:0.014279:0.015878:0.015878:0.012680:0.009510:0.005569:0.020619:0.015878:0.012169:0.014279:0.015878:0.012680:0.007140
Unveils A Lead Antitumor Agent Inhibiting Folded P-Loop :@0.104762:0.137337:0.827844:0.137337:0.827844:0.109391:0.104762:0.109391:0.020619:0.015878:0.014279:0.012680:0.007939:0.007939:0.011109:0.005563:0.019048:0.007140:0.019048:0.012680:0.014279:0.015878:0.005563:0.020619:0.015878:0.009510:0.007939:0.009510:0.015878:0.023789:0.014279:0.012169:0.005566:0.020619:0.014279:0.012680:0.015878:0.009510:0.007140:0.011109:0.015878:0.015878:0.007939:0.015878:0.007939:0.009510:0.007939:0.015878:0.014279:0.007140:0.017449:0.014279:0.007939:0.015878:0.012680:0.015878:0.007140:0.017449:0.009510:0.019048:0.014279:0.014279:0.015878:0.007140
Conformation Of Met Receptor Tyrosine Kinase:@0.104762:0.163466:0.693572:0.163466:0.693572:0.135520:0.104762:0.135520:0.020619:0.014279:0.015878:0.009510:0.014279:0.012680:0.023789:0.014279:0.009510:0.007939:0.014279:0.015878:0.007140:0.022218:0.009510:0.007140:0.026959:0.012680:0.009510:0.007140:0.020619:0.012680:0.012680:0.012680:0.015878:0.009510:0.014279:0.012149:0.006623:0.016929:0.014279:0.012160:0.014279:0.011109:0.007939:0.015878:0.012680:0.007140:0.022218:0.007939:0.015878:0.014279:0.011109:0.012680
Pharmaceuticals. 2023; 16(11): 1597.:@0.318546:0.188085:0.682406:0.188085:0.682406:0.165818:0.318546:0.165818:0.014370:0.013076:0.011759:0.009149:0.018297:0.011759:0.010442:0.010442:0.013076:0.006538:0.006538:0.010442:0.011759:0.006538:0.009149:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.007832:0.010447:0.011759:0.007832:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880
------------------------------------------------------------------------------------:@0.171532:0.214209:0.829392:0.214209:0.829392:0.191810:0.171532:0.191810:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Ahmed H. E. Hassan, Cai Yi Wang, Cheol Jung Lee, Hye Rim Jeon, Yeonwoo Choi, :@0.124208:0.239984:0.882204:0.239984:0.882204:0.219308:0.124208:0.219308:0.014566:0.012142:0.016990:0.009696:0.010919:0.005460:0.016990:0.005460:0.005460:0.014566:0.005460:0.005460:0.016990:0.010919:0.008495:0.008495:0.010919:0.012142:0.005460:0.005460:0.014566:0.010919:0.006071:0.005060:0.012136:0.006071:0.005060:0.017798:0.010919:0.012142:0.010919:0.005460:0.005460:0.014566:0.012142:0.009696:0.010919:0.006071:0.005460:0.010919:0.012142:0.012142:0.010919:0.005460:0.013343:0.009696:0.009696:0.005460:0.005460:0.016990:0.009696:0.009696:0.005460:0.014566:0.006071:0.016990:0.005460:0.010919:0.009696:0.010919:0.012142:0.005460:0.005043:0.010919:0.009696:0.010919:0.012142:0.014566:0.010919:0.010919:0.005460:0.014566:0.012142:0.010919:0.006071:0.005460:0.005460
Suyeon Moon, Chae Hyeon Lee, Yeon Ju Kim, Soo Bin Cho, Kazem Mahmoud, Selwan :@0.107523:0.266111:0.898902:0.266111:0.898902:0.245434:0.107523:0.245434:0.012142:0.012142:0.009696:0.009696:0.010919:0.012142:0.005460:0.019415:0.010919:0.010919:0.012142:0.005460:0.005460:0.014566:0.012142:0.010919:0.009696:0.005460:0.016990:0.009696:0.009696:0.010919:0.012142:0.005460:0.013343:0.009696:0.009696:0.005460:0.005058:0.010919:0.009696:0.010919:0.012142:0.005460:0.010919:0.012142:0.005460:0.014566:0.006071:0.016990:0.005460:0.005460:0.012142:0.010919:0.010919:0.005460:0.014566:0.006071:0.012142:0.005460:0.014566:0.012142:0.010919:0.005460:0.005460:0.014566:0.010919:0.008495:0.009696:0.016990:0.005460:0.019415:0.010919:0.012142:0.016990:0.010919:0.012142:0.010919:0.005460:0.005460:0.012142:0.009696:0.006071:0.014566:0.010919:0.012142:0.005460
M El-Sayed, Sang Kook Lee, Yong Sup Lee:@0.306254:0.292237:0.694711:0.292237:0.694711:0.271561:0.306254:0.271561:0.019415:0.005460:0.014566:0.006071:0.007272:0.012142:0.010919:0.009696:0.009696:0.010919:0.005460:0.005460:0.012142:0.010919:0.012142:0.010919:0.005460:0.014566:0.010919:0.010919:0.010919:0.005460:0.013343:0.009696:0.009696:0.005460:0.005058:0.010919:0.010919:0.012142:0.010919:0.005460:0.012142:0.012142:0.010919:0.005460:0.013343:0.009696:0.009696
Vol. 2 - Issue 1:@0.743337:0.965677:0.857137:0.965677:0.857137:0.947594:0.743337:0.947594:0.011649:0.009239:0.005137:0.004620:0.004620:0.009239:0.004620:0.006153:0.004620:0.007188:0.007188:0.007188:0.010274:0.008205:0.004620:0.009239
Reference::@0.104762:0.557158:0.210548:0.557158:0.210548:0.534891:0.104762:0.534891:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.3390/ph16111597:@0.104762:0.576687:0.345868:0.576687:0.345868:0.560687:0.104762:0.560687:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670:0.008399:0.008399:0.008399:0.008399:0.007771:0.007775:0.008399:0.008399:0.008399:0.008399
Abstract:@0.104762:0.323088:0.213026:0.323088:0.213026:0.295141:0.104762:0.295141:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
A library of 24 congeners of the natural product sulfuretin were evaluated against nine panels :@0.104762:0.344679:0.900451:0.344679:0.900451:0.325479:0.104762:0.325479:0.013647:0.006632:0.005806:0.005806:0.010281:0.006914:0.009152:0.006914:0.010281:0.006632:0.010281:0.006914:0.006632:0.010281:0.010281:0.006632:0.009152:0.010281:0.010281:0.010281:0.009152:0.010281:0.009152:0.006914:0.008043:0.006632:0.010281:0.006914:0.006632:0.005806:0.010281:0.009152:0.006632:0.010281:0.009152:0.005806:0.010281:0.006914:0.009152:0.005806:0.006632:0.010281:0.006914:0.010281:0.010281:0.010281:0.009152:0.005806:0.006632:0.008043:0.010281:0.005806:0.006914:0.010281:0.006914:0.009152:0.005806:0.005806:0.010281:0.006632:0.014756:0.009152:0.006914:0.009152:0.006632:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.005806:0.009152:0.010281:0.006632:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.006632:0.010281:0.005806:0.010281:0.009152:0.006632:0.010281:0.009152:0.010281:0.009152:0.005806:0.007846:0.005040
representing nine cancer diseases.  While sulfuretin elicited very weak activities at 10 µM :@0.104762:0.361783:0.900406:0.361783:0.900406:0.342584:0.104762:0.342584:0.006914:0.009152:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.005806:0.005806:0.010281:0.010281:0.009676:0.010281:0.005806:0.010281:0.009152:0.009676:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.009676:0.010281:0.005806:0.008043:0.009152:0.009152:0.008043:0.009152:0.008043:0.005241:0.005040:0.004270:0.019231:0.010281:0.005806:0.005806:0.009152:0.009676:0.008043:0.010281:0.005806:0.006914:0.010281:0.006914:0.009152:0.005806:0.005806:0.010281:0.009676:0.009152:0.005806:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.009676:0.010281:0.009152:0.006914:0.010281:0.009676:0.014756:0.009152:0.009152:0.010281:0.009676:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.005806:0.009152:0.008043:0.009676:0.009152:0.005806:0.009676:0.010281:0.010281:0.009676:0.011813:0.017925:0.005040
concentration, congener 1t was identified as a potential compound triggering growth inhibition :@0.104762:0.378888:0.900467:0.378888:0.900467:0.359688:0.104762:0.359688:0.009152:0.010281:0.010281:0.009152:0.009152:0.010281:0.005806:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.005886:0.009152:0.010281:0.010281:0.010281:0.009152:0.010281:0.009152:0.006914:0.005886:0.010281:0.005806:0.005886:0.014756:0.009152:0.008043:0.005886:0.005806:0.010281:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.010281:0.005886:0.009152:0.008043:0.005886:0.009152:0.005886:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.005806:0.009152:0.005806:0.005886:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.005886:0.005806:0.006914:0.005806:0.010281:0.010281:0.009152:0.006914:0.005806:0.010281:0.010281:0.005886:0.010281:0.006914:0.010281:0.014756:0.005806:0.010281:0.005886:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.005806:0.010281:0.010079:0.005040
of diverse cell lines. Mechanistic studies in HCT116 colon cancer cells revealed that congener :@0.104762:0.395992:0.900386:0.395992:0.900386:0.376792:0.104762:0.376792:0.010281:0.006914:0.006189:0.010281:0.005806:0.010281:0.009152:0.006914:0.008043:0.009152:0.006189:0.009152:0.009152:0.005806:0.005806:0.006189:0.005806:0.005806:0.010281:0.009152:0.008043:0.005241:0.006189:0.018123:0.009152:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.005806:0.005806:0.009152:0.006189:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.008043:0.006189:0.005806:0.010281:0.006189:0.014756:0.013647:0.012519:0.009533:0.010281:0.010281:0.006189:0.009152:0.010281:0.005806:0.010281:0.010281:0.006189:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.006189:0.009152:0.009152:0.005806:0.005806:0.008043:0.006189:0.006914:0.009152:0.010281:0.009152:0.009152:0.005806:0.009152:0.010281:0.006189:0.005806:0.010281:0.009152:0.005806:0.006189:0.009152:0.010281:0.010281:0.010281:0.009152:0.010281:0.009152:0.006715:0.005040
1t dose-dependently increased levels of cleaved-caspases 8 and 9 and cleaved-PARP, while it :@0.104762:0.413096:0.900459:0.413096:0.900459:0.393897:0.104762:0.393897:0.010281:0.005806:0.007116:0.010281:0.010281:0.008043:0.009152:0.006914:0.010281:0.009152:0.010281:0.009152:0.010281:0.010281:0.009152:0.010281:0.005806:0.005806:0.010281:0.007116:0.005806:0.010281:0.009152:0.006914:0.009152:0.009152:0.008043:0.009152:0.010281:0.007116:0.005806:0.009152:0.010281:0.009152:0.005806:0.008043:0.007116:0.010281:0.006914:0.007116:0.009152:0.005806:0.009152:0.009152:0.010281:0.009152:0.010281:0.006914:0.009152:0.009152:0.008043:0.010281:0.009152:0.008043:0.009152:0.008043:0.007116:0.010281:0.007116:0.009152:0.010281:0.010281:0.007116:0.010281:0.007116:0.009152:0.010281:0.010281:0.007116:0.009152:0.005806:0.009152:0.009152:0.010281:0.009152:0.010281:0.006914:0.009563:0.014756:0.013647:0.009178:0.005241:0.007116:0.014756:0.010281:0.005806:0.005806:0.009152:0.007116:0.005806:0.005602:0.005040
concentration-dependently decreased levels of CDK4, CDK6, Cdc25A, and Cyclin D and E :@0.104762:0.430201:0.900362:0.430201:0.900362:0.411001:0.104762:0.411001:0.009152:0.010281:0.010281:0.009152:0.009152:0.010281:0.005806:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.006914:0.010281:0.009152:0.010281:0.009152:0.010281:0.010281:0.009152:0.010281:0.005806:0.005806:0.010281:0.008305:0.010281:0.009152:0.009152:0.006914:0.009152:0.009152:0.008043:0.009152:0.010281:0.008305:0.005806:0.009152:0.010281:0.009152:0.005806:0.008043:0.008305:0.010281:0.006914:0.008305:0.013647:0.014756:0.014756:0.010281:0.005241:0.008305:0.013647:0.014756:0.014756:0.010281:0.005241:0.008305:0.013647:0.010281:0.009152:0.010281:0.010281:0.014756:0.005241:0.008305:0.009152:0.010281:0.010281:0.008305:0.013647:0.010281:0.009152:0.005806:0.005806:0.010281:0.008305:0.014756:0.008305:0.009152:0.010281:0.010281:0.008305:0.012313:0.005040
resulting in induction of cell cycle arrest and apoptosis in colon cancer HCT116 cells. Mechanistic :@0.104762:0.447305:0.900400:0.447305:0.900400:0.428106:0.104762:0.428106:0.006914:0.009152:0.008043:0.010281:0.005806:0.005806:0.005806:0.010281:0.010281:0.003528:0.005806:0.010281:0.003528:0.005806:0.010281:0.010281:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.003528:0.010281:0.006914:0.003528:0.009152:0.009152:0.005806:0.005806:0.003528:0.009152:0.010281:0.009152:0.005806:0.009152:0.003528:0.009152:0.006914:0.006914:0.009152:0.008043:0.005806:0.003528:0.009152:0.010281:0.010281:0.003528:0.009152:0.010281:0.010281:0.010281:0.005806:0.010281:0.008043:0.005806:0.008043:0.003528:0.005806:0.010281:0.003528:0.009152:0.010281:0.005806:0.010281:0.010281:0.003528:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.003528:0.014756:0.013647:0.012519:0.009533:0.010281:0.010281:0.003528:0.009152:0.009152:0.005806:0.005806:0.008043:0.005241:0.003528:0.018123:0.009152:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.005806:0.005806:0.008946:0.005040
study also presented MET receptor tyrosine kinase as the molecular target mediating the anticancer :@0.104762:0.464410:0.900340:0.464410:0.900340:0.445210:0.104762:0.445210:0.008043:0.005806:0.010281:0.010281:0.010281:0.003064:0.009152:0.005806:0.008043:0.010281:0.003064:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.005806:0.009152:0.010281:0.003064:0.018123:0.012519:0.012152:0.003064:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.003064:0.005806:0.010281:0.006914:0.010281:0.008043:0.005806:0.010281:0.009152:0.003064:0.010281:0.005806:0.010281:0.009152:0.008043:0.009152:0.003064:0.009152:0.008043:0.003064:0.005806:0.010281:0.009152:0.003064:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.003064:0.005806:0.009152:0.006550:0.010281:0.009152:0.005806:0.003064:0.015885:0.009152:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.003064:0.005806:0.010281:0.009152:0.003064:0.009152:0.010281:0.005806:0.005806:0.009152:0.009152:0.010281:0.009152:0.009152:0.006713:0.005040
activity of compound 1t in HCT116 cells. In silico study predicted folded p-loop conformation :@0.104762:0.481514:0.900370:0.481514:0.900370:0.462314:0.104762:0.462314:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.005937:0.010281:0.006914:0.005937:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.005937:0.010281:0.005806:0.005937:0.005806:0.010281:0.005935:0.014756:0.013647:0.012519:0.009533:0.010281:0.010281:0.005937:0.009152:0.009152:0.005806:0.005806:0.008043:0.005241:0.005937:0.006914:0.010281:0.005937:0.008043:0.005806:0.005806:0.005806:0.009152:0.010281:0.005935:0.008043:0.005806:0.010281:0.010281:0.010281:0.005937:0.010281:0.006914:0.009152:0.010281:0.005806:0.009152:0.005806:0.009152:0.010281:0.005937:0.006914:0.010281:0.005806:0.010281:0.009152:0.010281:0.005937:0.010281:0.006914:0.005806:0.010281:0.010281:0.010281:0.005937:0.009152:0.010281:0.010281:0.006914:0.010281:0.006914:0.015885:0.009152:0.005806:0.005806:0.010281:0.010079:0.005040
as the form of MET receptor tyrosine kinase responsible for binding of compound 1t. Together, :@0.104762:0.498618:0.900303:0.498618:0.900303:0.479419:0.104762:0.479419:0.009152:0.008043:0.005564:0.005806:0.010281:0.009152:0.005564:0.006914:0.010281:0.006914:0.015885:0.005564:0.010281:0.006914:0.005564:0.018123:0.012519:0.012152:0.005564:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.005564:0.005806:0.010281:0.006914:0.010281:0.008043:0.005806:0.010281:0.009152:0.005564:0.010281:0.005806:0.010281:0.009152:0.008043:0.009152:0.005564:0.006914:0.009152:0.008043:0.010281:0.010281:0.010281:0.008043:0.005806:0.010281:0.005806:0.009152:0.005564:0.006914:0.010281:0.006914:0.005564:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.005564:0.010281:0.006914:0.005564:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.005564:0.010281:0.005806:0.005241:0.005203:0.011107:0.010281:0.010281:0.009152:0.005806:0.010281:0.009152:0.006108:0.005040:0.005040
the current study presents compound 1t as an interesting anticancer lead for further development.:@0.104762:0.515723:0.895246:0.515723:0.895246:0.496523:0.104762:0.496523:0.005806:0.010281:0.009152:0.004354:0.009152:0.010281:0.006914:0.006914:0.009152:0.010281:0.005806:0.004354:0.008043:0.005806:0.010281:0.010281:0.010281:0.004354:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.005806:0.008043:0.004354:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.004354:0.010281:0.005806:0.004354:0.009152:0.008043:0.004354:0.009152:0.010281:0.004354:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.008043:0.005806:0.005806:0.010281:0.010281:0.004354:0.009152:0.010281:0.005806:0.005806:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.004354:0.005806:0.009152:0.009152:0.010281:0.004354:0.006914:0.010281:0.006914:0.004354:0.006914:0.010281:0.006914:0.005806:0.010281:0.009152:0.006914:0.004354:0.010281:0.009152:0.010281:0.009152:0.005806:0.010281:0.010281:0.015885:0.009152:0.010281:0.005806:0.005040
109:@0.864761:0.971012:0.911903:0.971012:0.911903:0.940075:0.864761:0.940075:0.015300:0.015300:0.016540